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Like total ghrelin, acylated ghrelin
is also lower in HD patients with
cardiovascular disease
To the Editor: Recently, Carrero et al.1 showed that lower
total plasma ghrelin is associated with increased total and
cardiovascular mortality in protein–energy wasting hemo-
dialysis (HD) patients. However, total ghrelin includes both
acylated and des-acylated forms, with different biological
actions.2
We assessed acylated ghrelin (A-Ghr) in 20 healthy volun-
teers (57.00±8.62 years) and 68 HD patients (61.24±12.51
years, 22 diabetics). Samples were drawn before 2 years,
and at the end of this period 22 HD patients suffered
from coronary heart disease (CHD). Plasma A-Ghr was
measured using enzyme-linked immunosorbent assay (SPI
Bio, Montigny, France). White blood cell count (WBC),
C-reactive protein (CRP), and albumin were also assessed.
A-Ghr did not differ between HD patients and healthy
volunteers (106.40±27.53 versus 120.50±45.04pg/ml, P¼ 0.424,
Mann–Whitney unpaired test). A-Ghr was lower in HD patients
suffering from CHD (95.00±22.04 versus 111.85±28.42pg/ml,
P¼ 0.023) and was positively correlated with WBC (Spearman’s
r¼ 0.426, Po0.001), CRP (r¼ 0.261, P¼ 0.023), that is, with
inﬂammation, and age (r¼ 0.323, P¼ 0.007). A-Ghr was
negatively correlated with the marker of nutrition albumin
(r¼0.368, P¼ 0.002).
Thus, similar to total ghrelin, A-Ghr is also lower in HD
patients with cardiovascular disease. This could be simply an
epiphenomenon, as in the case of cachexia that accompanies
inﬂammation, A-Ghr increases to counteract weight-loss
mechanisms, and it is well known that inﬂammation also
induces atherosclerosis.2,3 Alternatively, higher A-Ghr could
offer protection from atherosclerosis through its direct action
on the endothelium or indirectly by attenuating inﬂamma-
tion.2,4 The second case, if proved true, is promising for
pharmaceutical intervention in the near future.
1. Carrero JJ, Nakashima A, Qureshi AR et al. Protein-energy wasting modifies
the association of ghrelin with inflammation, leptin, and mortality in
hemodialysis patients. Kidney Int 2011; 79: 749–756.
2. Soares JB, Leite-Moreira AF. Ghrelin, des-acyl ghrelin and obestatin: three
pieces of the same puzzle. Peptides 2008; 29: 1255–1270.
3. Laviano A, Krznaric Z, Sanchez-Lara K et al. Chronic renal failure, cachexia,
and ghrelin. Int J Pept 2010; pii: 648045.
4. Tesauro M, Schinzari F, Caramanti M et al. Metabolic and cardiovascular
effects of ghrelin. Int J Pept 2010; pii: 864342.
Theodoros Eleftheriadis1,2, Georgia Antoniadi1,
Vassilios Liakopoulos1, Theodora Sparopoulou2,
Ioannis Stefanidis1 and Grammati Galaktidou2
1Department of Nephrology, University of Thessaly Medical School, Larissa,
Greece and 2Research Institute, Theagenion Anticancer Hospital,
Thessaloniki, Greece
Correspondence: Theodoros Eleftheriadis, Department of Nephrology,
University of Thessaly Medical School, Neo Ktirio, Mezourlo Hill,
41110 Larissa, Greece. E-mail: teleftheriadis@yahoo.com
Kidney International (2011) 80, 783; doi:10.1038/ki.2011.234
The Authors Reply: We thank Eleftheriadis et al.1 for their
interest in our work.2 We believe that our observations
regarding the confounding effect of pre-existing protein–
energy wasting on the associations of ghrelin with inﬂamma-
tion, leptin, and outcome2 help to reconcile apparent
discrepancies between epidemiological3 and interventional
studies4 on the existence of a resistance to the action of
ghrelin in chronic kidney disease. Their report that there is no
difference in acylated ghrelin between healthy volunteers and
hemodialysis patients, but reduced acylated ghrelin in patients
with cardiovascular disease, may as well represent, as they
indicate, the epiphenomenon of concurrent cachexia. The
inability of observational studies to denote causality in these
associations warrants altogether the need to delve deeper into
the effects of ghrelin administration in the outcome of dialysis
patients. Ghrelin is truly an exciting therapeutic agent with a
range of purported beneﬁcial effects not only on anorexia but
also on inﬂammation and the cardiac system, and new
treatment strategies to tackle the excess mortality of this
patient group are urgently needed. However, we still have
some questions to address: although animal studies suggest
that acylated ghrelin stimulates appetite, Barazzoni et al.5
postulated that relative acylated ghrelin excess could con-
tribute to obesity-associated insulin resistance in metabolic
syndrome. The risks of developing ghrelin resistance, its
mitogenic potential, and the costs for ghrelin treatment also
need consideration.6 Although a small-scale clinical trial4 has
provided encouraging evidence on the short-term orexigenic
effects of subcutaneous acylated ghrelin administration
(1 week) in malnourished dialysis patients, we need still
to proceed cautiously until these concerns are clariﬁed.
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Retinoic acid receptor-a in
HIV-associated nephropathy
To the Editor: We have read the paper by Ratnam et al.1
reporting that the expression of retinoic acid receptor-a
(RARA) target genes were suppressed in the kidneys of
HIV-1 transgenic mice (TG26), as well as those of patients
with HIV-associated nephropathy (HIVAN). The overall enzy-
matic activity for retinoic acid synthesis was signiﬁcantly
reduced in the glomeruli of TG26 mice, suggesting that a
defect in the synthesis of retinoic acid contributed to loss
of protection by retinoic acid in HIVAN. They postulated that
RARA agonists may be potential agents for treatment of
HIVAN.
In this regard, we would like to share a similar ﬁnding
with our recent work2 in IgA nephropathy (IgAN). Using
the GeneChip Human Genome U133 Plus 2.0 Arrays from
Affymetrix (Santa Clara, CA), a total of 7761 gene expressions
were identiﬁed that had an IgAN/normal gene expression
ratio of 0.06- to 5.58-fold (312 were upregulated with a
ratio X2.0-fold and 244 were downregulated with a ratio
p0.2-fold). An analysis of the expression of the 30 most
downregulated genes revealed that RARA was most down-
regulated in IgAN. Comparing the gene expression proﬁle of
patients with IgAN, non-IgAN (minimal change disease), and
normal controls, the RARA gene expression proﬁle was found
to be downregulated to 0.41-fold (231±77 vs 561±227 units,
Po0.005) in patients with IgAN compared with patients and
normal controls. Our ﬁnding of downregulation of RARA in
IgAN is similar to the ﬁnding of Ratnam et al.1 of suppression
of RARA target gene expression in TG26 mice and HIVAN
patients.
The ﬁnding of downregulating of mRNA expression for
RARA in IgAN may suggest a potential therapeutic approach
for IgAN. Shaier’s model of Thy-GN mice3 is akin to the
human disease of IgAN, as the Thy-GN mice have mesangial
proliferative glomerulonephritis (GN) similar to human
IgAN where there is also mesangial proliferative GN. In
Shaier’s report,3 Thy-GN mice treated with RARA agonist
had reduced proteinuria and normalization of blood pressure.
We postulate that RARA-speciﬁc retinoids may provide a
therapeutic approach to the therapy of IgAN. RARA belongs
to the steroid hormone superfamily of nuclear receptor
proteins, which exert their effects by binding speciﬁc DNA
response elements, thus regulating gene expression I target
cells.4,5 Regulating or normalizing RARA mRNA expression
in patients with IgAN may thus offer a novel therapeutic
approach in terms of gene therapy. This is especially relevant
to IgAN, which has hitherto no known speciﬁc therapy. In
this respect, we are in complete agreement with Ratnam’s
postulate that RARA agonists may be potential agents for
treatment of HIVAN.1
1. Ratnam KK, Feng X, Chuang PY et al. Role of retinoic acid receptor–a in
HIV-associated nephropathy. Kidney Int 2011; 79: 624–634.
2. Woo KT, Lau YK, Zhao Y et al. Urotensin2 and retinoic acid receptor
alpha (RARA) gene expression in IgA nephropathy. Ann Acad Med Sing
2010; 39: 705–713.
3. Schaier M, Liebler S, Schade K et al. Retinoic acid receptor a and retinoid X
receptor specific agonists reduce renal injury in established chronic
glomerulonephritis of the rat. J Mol Med 2004; 82: 116–125.
4. Watson RE, Arjuna Ratnayaka J, Brooke RC et al. Retinoic acid receptor
alpha expression and cutaneous ageing. Mech Ageing Dev 2004; 125:
465–473.
5. Ribot J, Felipe F, Bonet ML et al. Retinoic acid administration and vitamin A
status modulate retinoid X receptor alpha and retinoic acid receptor
alpha levels in mouse brown adipose tissue. Mol Cell Biochem 2004;
266: 25–30.
Keng Thye Woo1, Kok Seng Wong1 and
Choong Meng Chan1
1Department of Renal Medicine, Singapore General Hospital, Singapore,
Singapore
Correspondence: Keng Thye Woo, Department of Renal Medicine,
Singapore General Hospital, Outram Road, Singapore 169608, Singapore.
E-mail: woo.keng.thye@sgh.com.sg
Kidney International (2011) 80, 784; doi:10.1038/ki.2011.236
The Authors Reply: Woo et al1 performed a GeneChip
microarray using total leukoctye ribonucleic acid isolated
from patients with IgA nephropathy compared with those
with minimal change disease and normal controls. Through
this unbiased screening, they ﬁnd that retinoic acid receptor-a
(RARA) mRNA level is downregulated to 0.41-fold in patients
with IgA nephropathy compared with patients with minimal
change disease and normal controls. Their ﬁndings suggest
an important role of RARA and retinoic acid signaling
in patients with kidney disease. The role of retinoic acid
has been demonstrated in many animal models of kidney
disease.2 However, the studies of retinoic acid and RARA
in human disease are lacking. It would be interesting to
determine RARA expression in kidneys of patients with
IgA nephropathy and other kidney diseases. We were not
able to determine the level of RARA mRNA in kidneys
of patients with HIV-associated nephropathy. By immuno-
staining, we did not observe a difference in RARA in the
kidney between patients with HIV-associated nephropathy
and minimal change disease. Our data suggest that RARA-
mediated target gene expression is suppressed in kidneys
of HIV-1 transgenic mice because of impaired endo-
genous retinoic acid synthesis. Consistent with our ﬁndings,
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